Stock Scorecard



Stock Summary for Atossa Therapeutics Inc (ATOS) - $0.72 as of 3/28/2025 7:16:53 PM EST

Total Score

11 out of 30

Safety Score

17 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ATOS

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ATOS

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ATOS

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ATOS

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ATOS (17 out of 100)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 2
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 1
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for ATOS

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results - Atossa Therapeutics ( NASDAQ:ATOS ) 3/20/2025 1:13:00 PM
Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results 3/20/2025 1:13:00 PM
Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for ( Z ) -Endoxifen and Continued Engagement with FDA on Additional Indications 3/11/2025 12:15:00 PM
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care 2/5/2025 1:00:00 PM
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591 - Atossa Therapeutics ( NASDAQ:ATOS ) 1/30/2025 1:17:00 PM
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591 1/30/2025 1:17:00 PM
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 1/23/2025 1:15:00 PM
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with ( Z ) -endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium 12/12/2024 1:15:00 PM
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density - Atossa Therapeutics ( NASDAQ:ATOS ) 12/11/2024 1:15:00 PM
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density 12/11/2024 1:15:00 PM

Financial Details for ATOS

Company Overview

Ticker ATOS
Company Name Atossa Therapeutics Inc
Country USA
Description Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs in the areas of oncology and infectious diseases. The company is headquartered in Seattle, Washington.
Sector Name LIFE SCIENCES
Industry Name SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Most Recent Quarter 12/31/2024
Next Earnings Date 3/31/2025

Stock Price History

Last Day Price 0.72
Price 4 Years Ago 1.60
Last Day Price Updated 3/28/2025 7:16:53 PM EST
Last Day Volume 432,935
Average Daily Volume 534,406
52-Week High 2.31
52-Week Low 0.66
Last Price to 52 Week Low 9.09%

Valuation Measures

Trailing PE N/A
Industry PE 64.12
Sector PE 40.10
5-Year Average PE -3.94
Free Cash Flow Ratio 1.22
Industry Free Cash Flow Ratio 29.26
Sector Free Cash Flow Ratio 47.05
Current Ratio Most Recent Quarter 13.30
Total Cash Per Share 0.59
Book Value Per Share Most Recent Quarter 0.55
Price to Book Ratio 1.23
Industry Price to Book Ratio 5.12
Sector Price to Book Ratio 21.92
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 4.27
Sector Price to Sales Ratio Twelve Trailing Months 27.78
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 125,801,000
Market Capitalization 90,576,720
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -11.62%
Reported EPS 12 Trailing Months -0.20
Reported EPS Past Year -0.21
Reported EPS Prior Year -0.27
Net Income Twelve Trailing Months -26,911,000
Net Income Past Year -30,094,000
Net Income Prior Year -26,960,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 74,766,000
Total Cash Past Year 88,500,000
Total Cash Prior Year 110,890,000
Net Cash Position Most Recent Quarter 74,766,000
Net Cash Position Past Year 88,500,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 91,016,000
Total Stockholder Equity Prior Year 117,964,000
Total Stockholder Equity Most Recent Quarter 73,681,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -19,528,000
Free Cash Flow Per Share Twelve Trailing Months -0.16
Free Cash Flow Past Year -20,914,000
Free Cash Flow Prior Year -20,787,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.02
MACD Signal -0.03
20-Day Bollinger Lower Band 0.55
20-Day Bollinger Middle Band 0.93
20-Day Bollinger Upper Band 1.32
Beta 1.20
RSI 43.71
50-Day SMA 1.22
150-Day SMA 1.00
200-Day SMA 1.41

System

Modified 3/28/2025 6:15:22 PM EST